Press release
An overview of clinical and preclinical research in Malignant Pleural Mesothelioma, highlighting major companies involved, therapeutic evaluations, upcoming treatments, treatment strategies
Malignant Pleural Mesothelioma pipeline developments
Malignant Pleural Mesothelioma Pipeline constitutes 20+ key companies continuously working towards developing 20+ Malignant Pleural Mesothelioma treatment therapies, analyzes DelveInsight.
Malignant Pleural Mesothelioma Overview:
Malignant pleural mesothelioma (MPM) is an aggressive cancer that affects the lining of the lungs. It is most often associated with past exposure to asbestos, with a latency period of approximately 40 years between exposure and the development of the disease. The global incidence of MPM has been gradually rising over the last decade and is expected to peak around 2020. The outlook for MPM is generally poor, with median survival rates ranging from 8 to 14 months post-diagnosis. Women tend to have a slightly better prognosis than men, but since the disease is largely occupational, it is more prevalent in men, with a male-to-female ratio of 4:1. MPM is classified into four main histological subtypes: epithelioid, sarcomatoid, biphasic (mixed), and desmoplastic. Asbestos exposure, often occurring over 40 years ago, is the primary cause of most cases, though other factors include exposure to erionite (a mineral found in Turkey), chest wall radiation, and the simian virus.
Download malignant pleural mesothelioma pipeline insights report @ https://www.delveinsight.com/report-store/malignant-pleural-mesothelioma-mpm-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Malignant Pleural Mesothelioma Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Malignant Pleural Mesothelioma Therapeutics Market.
Key Takeaways from the Malignant Pleural Mesothelioma Pipeline Report
*
DelveInsight's Malignant Pleural Mesothelioma (MPM) pipeline report highlights a dynamic landscape with over 20 active companies developing more than 20 potential therapies for the treatment of MPM.
*
In September 2024, the FDA approved Merck's KEYTRUDA Registered (pembrolizumab) in combination with pemetrexed and platinum chemotherapy as a first-line treatment for adult patients with unresectable advanced or metastatic MPM.
*
Key players in the MPM space, including MolMed, PharmaMar, Ys Therapeutics, Merck Sharp & Dohme Corp., Kissei Pharmaceutical Co., Ltd., NovoCure Ltd., AGC Biologics S.p.A., Aduro Biotech, Inc., Novartis, Bristol-Myers Squibb, TCR2 Therapeutics, Novotech (Australia) Pty Limited, AstraZeneca, Hoffmann-La Roche, Polaris Pharmaceuticals, Kyorin Pharmaceuticals, ACADIA Pharmaceuticals, and others, are actively researching and developing new treatments to improve the current MPM therapeutic options.
*
Notable pipeline therapies showing promise in various stages of development include Semaglutide, ACP 01, Revacept, among others.
Malignant Pleural Mesothelioma Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Malignant Pleural Mesothelioma Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Malignant Pleural Mesothelioma treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Malignant Pleural Mesothelioma market.
Request for a detailed informative report on malignant plural mesothelioma pipeline insights [https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-mpm-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Malignant Pleural Mesothelioma Emerging Drugs
*
NGR-TNF: MolMed
*
Pembrolizumab : Merck & Co
*
Pegargiminase: Polaris Pharmaceuticals
*
Lurbinectedin: PharmaMar
*
YS110: Ys Therapeutics
Malignant Pleural Mesothelioma Companies
Over 20 major companies are working on developing therapies for Malignant Pleural Mesothelioma. Among them, MolMed has drug candidates for the condition in the most advanced stage, specifically Phase III.
DelveInsight's report covers around 22+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Malignant Pleural Mesothelioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Malignant Pleural Mesothelioma Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Malignant Pleural Mesothelioma Therapies and Key Companies: Malignant Pleural Mesothelioma Clinical Trials and advancements [https://www.delveinsight.com/report-store/malignant-pleural-mesothelioma-mpm-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Malignant Pleural Mesothelioma Pipeline Therapeutic Assessment
- Malignant Pleural Mesothelioma Assessment by Product Type
- Malignant Pleural Mesothelioma By Stage
- Malignant Pleural Mesothelioma Assessment by Route of Administration
- Malignant Pleural Mesothelioma Assessment by Molecule Type
Download Malignant Pleural Mesothelioma Sample report to know in detail about the Malignant Pleural Mesothelioma treatment market @ Malignant Pleural Mesothelioma Therapeutic Assessment [https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-mpm-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Malignant Pleural Mesothelioma Current Treatment Patterns
4. Malignant Pleural Mesothelioma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Malignant Pleural Mesothelioma Late-Stage Products (Phase-III)
7. Malignant Pleural Mesothelioma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Malignant Pleural Mesothelioma Discontinued Products
13. Malignant Pleural Mesothelioma Product Profiles
14. Malignant Pleural Mesothelioma Key Companies
15. Malignant Pleural Mesothelioma Key Products
16. Dormant and Discontinued Products
17. Malignant Pleural Mesothelioma Unmet Needs
18. Malignant Pleural Mesothelioma Future Perspectives
19. Malignant Pleural Mesothelioma Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Malignant Pleural Mesothelioma Pipeline Reports Offerings [https://www.delveinsight.com/report-store/malignant-pleural-mesothelioma-mpm-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=an-overview-of-clinical-and-preclinical-research-in-malignant-pleural-mesothelioma-highlighting-major-companies-involved-therapeutic-evaluations-upcoming-treatments-treatment-strategies]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release An overview of clinical and preclinical research in Malignant Pleural Mesothelioma, highlighting major companies involved, therapeutic evaluations, upcoming treatments, treatment strategies here
News-ID: 4078690 • Views: …
More Releases from ABNewswire
Narcolepsy Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessm …
DelveInsight's, "Narcolepsy - Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Narcolepsy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Narcolepsy Pipeline constitutes 15+ key companies continuously working towards developing 20+ Narcolepsy…
Von Willebrand Disease: Clinical and Preclinical Studies, Leading Companies, The …
DelveInsight's, "Von Willebrand's Disease - Pipeline Insight, 2025" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Von Willebrand's Disease pipeline landscape.
Von Willebrand Disease Pipeline constitutes 3 + key companies continuously working towards developing 3+ Von Willebrand Disease treatment therapies, analyzes DelveInsight.
Von Willebrand Disease Overview:
Von Willebrand disease (VWD) is the most prevalent inherited bleeding disorder, resulting from a deficiency or malfunction of von Willebrand factor (VWF), a…
Rethinking Acne: Texas-Based Practitioner Offers Root-Cause Approach Amid Rising …
Dallas-Fort Worth, TX - Jun 23, 2025 - As the U.S. acne treatment market continues to grow-projected to reach $7.27 billion by 2030-one Texas-based consultant is offering a radically different path forward, focused not on topical fixes or pharmaceuticals, but on the body's own internal signals.
Michelle Valeri, founder of MV Skin Consulting and a best-selling author, has spent years developing a method of acne treatment that views breakouts not as…
The Historical Novel "Thunder in the Wind" investigates what happens to a people …
Author Curt Orloff's sweeping tale of deculturization delivers a timeless message of resilience, relevance, and reckoning
In Thunder in the Wind [https://www.amazon.com/Thunder-Wind-Curt-Orloff/dp/1963565347/ref=monarch_sidesheet_image], author Curt Orloff delivers an unflinching portrait of a people caught in the storm of historical transformation. Set mostly on the Fort Belknap reservation in Montana in the late 1800s, this novel explores how ordinary people responded to the tumultuous situation of an indifferent bureaucracy and a society blinded…
More Releases for Malignant
Malignant Mesothelioma-Pipeline Review H2 2018
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Human Parainfluenza Virus 3 Infections-Pipeline Review, H2 2018, provides an overview of the Human Parainfluenza Virus 3 Infections (Infectious Disease) pipeline landscape.
Human parainfluenza virus 3 is a life-threatening infection that causes respiratory illnesses in infants and young children. Symptoms include fever, cough, runny nose, croup, bronchiolitis, wheezing and sore throat. Treatment includes over-the-counter medications for pain and fever.
Report Highlights
Publisher's Pharmaceutical…
Malignant Mesothelioma-Pipeline Review H2 2018
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Mesothelioma-Pipeline Review, H2 2018, provides an overview of the Malignant Mesothelioma (Oncology) pipeline landscape.
Malignant pleural mesothelioma is a rare cancer often diagnosed in people who have been exposed to high levels of asbestos. The malignancy affects the pleura, a thin membrane of lubricating cells that lines the lungs and chest wall. Peritoneal mesothelioma originates in the abdomen and as a result,…
Malignant Ascites Treatment Market Opportunity Analysis - 2026
Ascites is the condition characterized by formation of excessive fluid in the abdominal cavity, particularly in the peritoneal cavity. It causes when the body is unable to eliminate out fluids. When ascites is developed due to cancer, it is called as malignant peritoneal effusion or malignant ascites. Malignancies that are most commonly associated with malignant ascites are cancers of breast, liver, ovary, lungs, lymphoma, and colon. In ascites condition, lymph…
Malignant Melanoma Drug Market Malignant Melanoma Clinical Pipeline Report
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to Malignant Melanoma
2. Malignant Melanoma Drug Mechanism of Action
3. Global Malignant Melanoma Market Analysis
3.1 Current Market Scenario
3.2 Global Malignant Melanoma Pipeline Overview
4. Global Malignant Melanoma Drug Market Dynamics
4.1 Favorable Market Parameters
4.2 Commercialization Challenges
5. Global Malignant Melanoma Drug Market Future Prospects
6. Global Malignant Melanoma Clinical Pipeline By…
Rising Number of People Diagnosed with Malignant Glioma Supports the Growth of t …
Glioma is a type of tumor that occurs in brain or spine. It is a group of brain tumor that includes oligodendrogliomas and astrocytomas. Gliomas include all types of brain tumors arising from supportive tissue of the brain. Malignant glioma is the most common type of brain tumor observed in adults globally. Collectively they contribute around 40% of the total cases diagnosed with brain tumor. In the last decade, there…
Malignant Mesothelioma - Pipeline Review, H1 2017-2022
Click here to Get free PDF Sample : http://www.marketresearchglobe.com/request-sample/241539
Market Research Globe latest Pharmaceutical and Healthcare disease pipeline guide Malignant Mesothelioma – Pipeline Review, H1 2017, provides an overview of the Malignant Mesothelioma (Oncology) pipeline landscape.
Malignant pleural mesothelioma is a rare cancer often diagnosed in people who have been exposed to high levels of asbestos. The malignancy affects the pleura, a thin membrane of lubricating cells that lines…
